Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOG), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc. reports developments as a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, with ZUNVEYL oral tablets as its commercial product for Alzheimer’s disease. Company news commonly covers financial results, business updates, long-term care commercialization, and the commercial and clinical positioning of its lead assets.
Updates also address ALPHA-1062 development, including programs related to Alzheimer’s dementia and cognitive impairment with mild traumatic brain injury, as well as patent activity for traumatic brain injury applications. Other recurring announcements include investor conference participation, board composition, executive and employee equity awards, and Nasdaq-related governance disclosures.
Alpha Cognition (ACOG) granted an inducement award of nonstatutory stock options to purchase 25,000 common shares to a new non-executive employee on September 8, 2026, under its 2026 Inducement Grant Plan in line with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $9.52 per share, equal to the closing price of the company’s stock on the grant date. Vesting occurs over three years: one-third on the first anniversary of the grant, and the remaining two-thirds in equal quarterly installments over the following two years, subject to continued service. The options are governed by the 2026 Inducement Grant Plan and an applicable stock option agreement. Alpha Cognition is a commercial-stage biopharmaceutical company focused on neurodegenerative diseases and markets the Alzheimer’s treatment ZUNVEYL.
Alpha Cognition (NASDAQ: ACOG) reported that its Board Compensation Committee granted an inducement award of nonstatutory stock options to purchase 20,000 common shares to a new non-executive employee under the 2026 Inducement Grant Plan. The options, granted August 31, 2026, have an exercise price of $9.27 per share, equal to the closing market price that day. Vesting will occur over three years, with one-third after the first anniversary and the remaining two-thirds in equal quarterly installments over the following two years, subject to continued service. The grant was approved as a material inducement to employment in line with Nasdaq Listing Rule 5635(c)(4).
Alpha Cognition (NASDAQ: ACOG) was the subject of an updated coverage report by Stonegate Capital Partners following 2Q26 results that support the ongoing launch of ZUNVEYL. Net product revenue rose 71% quarter-over-quarter to $6.0 million, driven by a 37% increase in bottles dispensed to 8,294, with June reaching 2,997 bottles, the strongest month since launch. Stonegate notes there was no material stocking benefit and downstream PBM implementation remained at about 16%.
Prescriber and facility adoption expanded, with 1,347 quarterly prescribers, 1,024 repeat prescribers, 1,908 cumulative writers and 1,095 long-term care facilities generating prescriptions. Alpha Cognition lowered FY26 R&D and SG&A guidance to $50–$54 million while maintaining its 2027 operating profitability target. According to the company, CONVERGE data are expected in 3Q26, RESOLVE is underway and the sublingual program depends on comparative PK results, creating several upcoming milestones.
Alpha Cognition (NASDAQ: ACOG) reported Q2 2026 ZUNVEYL net product revenue of approximately $6.0 million, up about 71% quarter-over-quarter from $3.5 million. Bottles dispensed rose 37% to 8,294, quarterly prescribers increased 26% to 1,347, and repeat prescribers grew 29% to 1,024, with roughly 76% prescribing in multiple months.
Long-term care penetration reached 1,095 facilities. Gross margin was 94%, with cost of product sales of $0.35 million. R&D expenses were $2.0 million and SG&A $11.5 million, driving an operating loss of $7.8 million and net loss of $8.8 million ($0.40 per share). Cash and equivalents totaled $41.4 million, and full-year 2026 R&D and SG&A guidance was reduced to $50–$54 million. The company highlighted positive BEACON study topline results, ongoing CONVERGE and RESOLVE studies, and a sublingual formulation targeting the clinic in 2027.
Alpha Cognition (Nasdaq: ACOG) will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. A press release with results and highlights will be posted in the News section of the company’s website.
According to Alpha Cognition, management will host a conference call and webcast to review financial and operating results. Investors can join via toll-free number 1-877-407-9039, international number 1-201-689-8470, Call me link, or webcast. A replay will be available about three hours after the call in the Events section of the website, with replay dial-in 1-844-512-2921 or 1-412-317-6671 using Access ID 137611178.
Alpha Cognition (NASDAQ: ACOG) announced that the European Patent Office has granted a patent covering a specific crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for treating mild-to-moderate Alzheimer’s disease. The patent covers the crystalline form, related formulations, manufacturing methods and medical-use claims.
According to Alpha Cognition, this grant strengthens its global intellectual property portfolio and may provide patent protection for benzgalantamine’s development and potential commercialization into 2042, subject to patent requirements. The patent may be validated in applicable EPC member states, expanding IP protection across key European Union and non-EU markets, including Switzerland and the United Kingdom.
Alpha Cognition (Nasdaq: ACOG) announced that CEO Michael McFadden will participate in the Late-Stage & Commercial CNS Small Cap panel at the B. Riley Securities Mind, Muscle & Vision Summit on July 16 in Boston, Massachusetts. The panel is scheduled from 3:10 p.m. to 3:50 p.m. ET. Investors can contact their B. Riley institutional representative for event details or to arrange 1x1 meetings. There will be no live webcast of the panel.
Alpha Cognition (Nasdaq: ACOG) elected Dr. Robert Wills as Chairman of the Board, succeeding retiring chair Len Mertz.
Dr. Wills has served on the board since 2025 and holds leadership roles at several biopharma companies, as Alpha Cognition advances ZUNVEYL’s commercial launch and its neurodegenerative pipeline.
Alpha Cognition (NASDAQ:ACOG) enrolled the first patient in RESOLVE, a Phase 4 post-marketing study of ZUNVEYL in mild to moderate Alzheimer’s disease. This multicenter trial will assess tolerability, safety and treatment experience in real-world outpatient practice.
The study plans to enroll about 150 patients, monitoring adverse events, treatment persistence and discontinuation rates, and exploring changes in Alzheimer’s-related neuropsychiatric symptoms. Enrollment is expected to continue through Q2 2027, with topline results anticipated after enrollment and follow-up are complete.
Alpha Cognition (NASDAQ: ACOG) reported positive top-line results from the BEACON real-world study of ZUNVEYL in long-term care residents with mild to moderate Alzheimer’s disease.
Among 162 patients followed for 3–12 months, providers reported high rates of cognitive, behavioral, functional and tolerability improvements, though the retrospective, uncontrolled design cannot establish causality.